News

MedPage Today on MSN16d
Heart Attack Mix-Ups; New Transplant Risk Score; Discounted Direct-to-Patient DOAC
The BMS-Pfizer Alliance announced a new direct-to-patient option for purchasing discounted apixaban (Eliquis) beginning in September.
Cardiotoxicity Treatment Market Set For Robust Growth Through 2032, Driven By Biomarker-Guided Monitoring And Personalized Prevention Delveinsight
The market report provides current cardiotoxicity treatment practices, emerging drugs, market share of individual therapies, ...